The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia

• Published in: Chung-hua nei kʿo tsa chih Vol. 50; no. 1; p. 48
• Main Authors: Song, Yan-ping, Tong, Yin, Qian, Wen-bin, Mai, Wen-yuan, Meng, Hai-tao, Qian, Ji-jing, Tong, Hong-yan, Huang, Jian, Mao, Li-ping, Xu, Wei-lai, Jin, Jie
• Format: Journal Article
• Language: Chinese
• Published: China 01.01.2011
• Subjects: Aclarubicin - administration & dosage; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cytarabine - administration & dosage; Disease-Free Survival; Female; Harringtonines - administration & dosage; Humans; Leukemia, Myeloid, Acute - drug therapy; Male; Middle Aged; Survival Rate; Treatment Outcome; Young Adult
• ISSN: 0578-1426

To explore the efficacy and safety of HAA regimen (homoharringtonine, cytarabine and aclarubicin) in the treatment of 150 newly diagnosed adult acute myeloid leukemia (AML). All patients entered the study from May 1999 to June 2008 were treated with HAA regimen. Cox-survival analysis was used to estimate the survival rate and differences between M(1)/M(2) and M(4)/M(5) were compared with 2-sided log-rank test. Out of the 150 patients, 121 (81%) achieved complete remission (CR). After the first course, CR rate was 68%. The CR rates of 97%, 84% and 38% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For the patients with CR, the median follow-up time was 16.5 (1.5 - 100.5) months, and the estimated 3-year survival rate was 45%. The estimated 3-year relapse free survival rate was 52% for the 121 patients with CR. HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be